Adding erlotinib to bevacizumab/chemoradiotherapy regimen for pancreatic cancer safe, tolerable

June 19, 2012

The addition of high doses of erlotinib to the treatment regimen of bevacizumab and capecitabine with radiotherapy seems to benefit patients with locally advanced pancreatic cancer, according to results of a phase I study presented at the American Association for Cancer Research's Pancreatic Cancer: Progress and Challenges conference, held here June 18-21.

"The combination of erlotinib, , and radiation was safe, well tolerated and showed promising activity in patients with unresectable, locally advanced ," said Christopher H. Crane, M.D., professor, program director and section chief, gastrointestinal section, department of , The University of Texas MD Anderson Cancer Center in Houston.

A total of 17 patients with CT-staged, biopsy-proven, nonmetastatic, unresectable, locally advanced pancreatic cancer were enrolled in the phase I clinical trial from March 2008 to October 2010. A combination of bevacizumab, capecitabine and radiotherapy has been previously shown to be safe. The objective of this study was to determine the safety, tolerability and maximum tolerated dose of a combination of erlotinib, bevacizumab and capecitabine given with concurrent radiation.

Two patients were enrolled at dose levels (DLs) one to four, and nine patients at DL five. Following drug escalation, the patients were reassessed for potential surgical resection of their tumors.

"Of five patients who underwent margin-negative resections, four had tumors that were originally deemed unresectable; four were treated at DLs four or five; three patients had excellent pathological responses at pancreatectomy and are alive at 13, 21 and 22 months respectively with no local or distant failures," the researchers wrote in the study.

"We were pleasantly surprised by the long median survival duration (23.6 months from diagnosis) and high degree of pathologic response among the five patients that were able to have surgery," Crane said. "Importantly, there was also a very low toxicity rate. All of the events reported were known effects of the drugs or radiation."

A total of three patients at DL five developed a grade 3 acute toxicity (two with diarrhea and one with rash). Grade 4 or 5 toxicities were not seen. DL four was selected as the recommended dose.

"This is the third single-arm study using concurrently with radiotherapy that has resulted in encouraging median survival duration," Crane said. "Based on our results, we suggest further studies are warranted using this combination in patients with locally advanced pancreatic cancer."

Explore further: RTOG initiates a phase I trial testing the therapy ganitumab for locally advanced pancreatic cancer

More information:

Abstract

Phase I Trial of Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Locally Advanced Pancreatic Cancer (LAPC). Heath D. Skinner, Christopher H. Crane, Sunil Krishnan, Milind M. Javle, Robert A. Wolff, Jason B. Fleming, Marilyn V. Clemons, Mark F. Munsell, Marc E. Delclos, Prajnan Das. University of Texas M. D. Anderson Cancer Center, Houston, TX.

Background: The addition of bevacizumab to chemoradiotherapy (CRT) for LAPC has been shown to be safe. The objective of this study was to determine the safety, tolerability and maximum tolerated dose (MTD) of the addition of erlotinib to this treatment regimen.

Methods: Seventeen patients with CT-staged biopsy-proven non-metastatic unresectable LAPC were enrolled between March 2008 and October 2010. Prior chemotherapy was permitted. All patients received 50.4 Gy (GTV only) in 28 fractions with concurrent capecitabine, bevacizumab and erlotinib. Dose was escalated using a continual reassessment method. Two patients each were enrolled at dose levels (DLs) 1-4 and 9 patients at DL 5. Bevacizumab was escalated from 5mg/Kg every two weeks (DLs 1-4) to 10mg/Kg (DL 5); erlotinib from 100 mg/day (DLs 1-2) to 150 mg/day (DLs 3-5); and capecitabine from 400mg/m2 twice daily on days of radiation (DL 1) to 600mg/m2 (DLs 2-3) to 825 mg/m2 (DLs 4-5). Reassessment for potential resection was performed 6-8 weeks later.

Results: With a median follow-up of 10 months (range 3-23), no grade 3 toxicities were observed in DLs 1-4. Three (33%) patients at DL 5 developed a grade 3 acute toxicity (2 diarrheas and 1 rash). No grade 4 or 5 toxicities were seen. DL 4, with a posterior probability of 0.122 of dose limiting toxicity, was selected as the MTD. Median survival was 19.4 months and time to distant progression was 9.8 months. Patients treated at DLs 4 and 5 had a median survival of 24 months. Of 5 patients who underwent margin-negative resections, 4 were originally deemed unresectable and 1 was borderline; 4 were treated at DLs 4 or 5 (36% of patients treated at these dose levels); 3 patients had excellent pathological responses (complete response, 5% viable tumor, and 20% viable tumor) at pancreatectomy and are alive at 13, 21 and 22 months respectively with no local or distant failures.

Conclusions: The combination of erlotinib, bevacizumab and capecitabine with radiotherapy for LAPC is safe and tolerable. Both the promising survival and the high rate of resectability at the higher dose levels suggest that this strategy of dual inhibition of growth factor receptor pathways during CRT warrants continued evaluation.

Related Stories

RTOG initiates a phase I trial testing the therapy ganitumab for locally advanced pancreatic cancer

December 14, 2011
Over 17,000 patients will have been diagnosed with locally-advanced pancreatic cancer in the United States in 2011. Surgery is not a treatment option for these patients whose tumor has grown beyond the pancreas to surrounding ...

Chemo plus radiation before surgery increases tumor response for rectal cancer

September 26, 2011
Rectal cancer patients who use a new combination of the chemotherapy, Capecitabine, together with five weeks of radiation (50 Gy) before surgery have an 88 percent chance of surviving the cancer three years after treatment, ...

Less toxic combination of erlotinib and bevacizumab is effective non-small cell lung cancer patients

June 1, 2011
The standard treatment for patients with advanced non-small cell lung cancer (NSCLC) is a combination of two old-fashioned cytotoxic chemotherapy drugs. The combination, however, comes with substantial toxicity. Now, Fox ...

Recommended for you

Vitamin C may encourage blood cancer stem cells to die

August 17, 2017
Vitamin C may "tell" faulty stem cells in the bone marrow to mature and die normally, instead of multiplying to cause blood cancers. This is the finding of a study led by researchers from Perlmutter Cancer Center at NYU Langone ...

Outdoor light at night linked with increased breast cancer risk in women

August 17, 2017
Women who live in areas with higher levels of outdoor light at night may be at higher risk for breast cancer than those living in areas with lower levels, according to a large long-term study from Harvard T.H. Chan School ...

Scientists develop novel immunotherapy technology for prostate cancer

August 17, 2017
A study led by scientists at The Wistar Institute describes a novel immunotherapeutic strategy for the treatment of cancer based on the use of synthetic DNA to directly encode protective antibodies against a cancer specific ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...

Researchers find 'switch' that turns on immune cells' tumor-killing ability

August 16, 2017
Molecular biologists led by Leonid Pobezinsky and his wife and research collaborator Elena Pobezinskaya at the University of Massachusetts Amherst have published results that for the first time show how a microRNA molecule ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.